Development of ipilimumab: A novel immunotherapeutic approach for the treatment of advanced melanoma.
Annals of the New York Academy of Sciences.
Times cited: 176
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
New England Journal of Medicine.
Times cited: 2902
Improved endpoints for cancer immunotherapy trials.
Journal of the National Cancer Institute.
Times cited: 406
Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria.
Clinical Cancer Research.
Times cited: 1957